Literature DB >> 16849417

Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men.

Howard A Fink1, Susan K Ewing, Kristine E Ensrud, Elizabeth Barrett-Connor, Brent C Taylor, Jane A Cauley, Eric S Orwoll.   

Abstract

CONTEXT: The clinical value of measuring testosterone and estradiol in older men with osteoporosis and of measuring bone mineral density (BMD) in older men with testosterone or estradiol deficiency is uncertain.
OBJECTIVE: The objective of the study was to examine the association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men.
DESIGN: This study was a cross-sectional and longitudinal analysis.
SETTING: The study was conducted at six U.S. centers of the Osteoporotic Fractures in Men study. PARTICIPANTS: The study population consisted of 2447 community-dwelling men aged 65 yr or older. MAIN OUTCOME MEASURES: Total testosterone deficiency was defined as less than 200 ng/dl. Total estradiol deficiency was defined as less than 10 pg/ml. Osteoporosis was defined as femoral neck or total hip BMD T-score of -2.5 or less. Rapid bone loss was defined as 3%/yr or more.
RESULTS: Prevalence of osteoporosis in men with deficient and normal total testosterone was 12.3 and 6.0% (P = 0.003) and 15.4 and 2.8% (P < 0.0001) in those with deficient and normal total estradiol. Among osteoporotic men and those with normal BMD, prevalence of total testosterone deficiency was 6.9 and 3.2% (P = 0.01), and prevalence of total estradiol deficiency was 9.2 and 2.4% (P = 0.0001). Incidence of rapid hip bone loss in men with deficient and normal total testosterone was 22.5 and 8.6% (p = 0.007) and in those with deficient and normal total estradiol was 14.3 and 6.3% (p = 0.08).
CONCLUSIONS: Older men with total testosterone or estradiol deficiency were more likely to be osteoporotic. Those with osteoporosis were more likely to be total testosterone or estradiol deficient. Rapid hip bone loss was more likely in men with total testosterone deficiency. BMD testing of older men with sex steroid deficiency may be clinically warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849417     DOI: 10.1210/jc.2006-0173

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  95 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Battle of the sex steroids in the male skeleton: and the winner is....

Authors:  Thomas J Weber
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

3.  Gonadal steroid-dependent effects on bone turnover and bone mineral density in men.

Authors:  Joel S Finkelstein; Hang Lee; Benjamin Z Leder; Sherri-Ann M Burnett-Bowie; David W Goldstein; Christopher W Hahn; Sarah C Hirsch; Alex Linker; Nicholas Perros; Andrew B Servais; Alexander P Taylor; Matthew L Webb; Jonathan M Youngner; Elaine W Yu
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

Review 4.  The genetics of bone loss: challenges and prospects.

Authors:  Braxton D Mitchell; Laura M Yerges-Armstrong
Journal:  J Clin Endocrinol Metab       Date:  2011-02-23       Impact factor: 5.958

Review 5.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

Review 6.  The pathogenesis, treatment and prevention of osteoporosis in men.

Authors:  Leif Mosekilde; Peter Vestergaard; Lars Rejnmark
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

7.  Gonadal sex steroid status and bone health in middle-aged and elderly European men.

Authors:  D Vanderschueren; S R Pye; K Venken; H Borghs; J Gaytant; I T Huhtaniemi; J E Adams; K A Ward; G Bartfai; F F Casanueva; J D Finn; G Forti; A Giwercman; T S Han; K Kula; F Labrie; M E J Lean; N Pendleton; M Punab; A J Silman; F C W Wu; T W O'Neill; S Boonen
Journal:  Osteoporos Int       Date:  2009-12-15       Impact factor: 4.507

Review 8.  The osteoporotic male: overlooked and undermanaged?

Authors:  Bruno Madeo; Lucia Zirilli; Giovanni Caffagni; Chiara Diazzi; Alessia Sanguanini; Elisa Pignatti; Cesare Carani; Vincenzo Rochira
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

Review 9.  The many faces of testosterone.

Authors:  Jerald Bain
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.